MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics


MeiraGTx Holdings plc - Ordinary Shares (MGTX)

Today's Latest Price: $14.78 USD

0.31 (-2.05%)

Updated Jan 27 4:00pm

Add MGTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MGTX Stock Price Chart Interactive Chart >

Price chart for MGTX

MGTX Price/Volume Stats

Current price $14.78 52-week high $21.77
Prev. close $15.09 52-week low $8.82
Day low $13.95 Volume 281,137
Day high $15.18 Avg. volume 117,308
50-day MA $14.94 Dividend yield N/A
200-day MA $13.96 Market Cap 567.73M

MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio


MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.


MGTX Latest News Stream


Event/Time News Detail
Loading, please wait...

MGTX Latest Social Stream


Loading social stream, please wait...

View Full MGTX Social Stream

Latest MGTX News From Around the Web

Below are the latest news stories about MeiraGTx Holdings plc that investors may wish to consider to help them evaluate MGTX as an investment opportunity.

MeiraGTx's AAV-CNGA3 Fast Track'd in U.S. for inherited retinal disease

The FDA grants Fast Track designation to MeiraGTx Holdings' (MGTX) AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia ((ACHM)) caused by mutations in the CNGA3 gene.Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application. ACHM is...

Seeking Alpha | January 26, 2021

MeiraGTx: Early Stage Gene Therapy Developer For Eye Diseases

MeiraGTx (MGTX) has an interesting early to mid stage gene therapy pipeline in a number of rare ocular diseases, and a partnership with Janssen (JNJ). The company has two platforms - a viral vector platform and a riboswitch-based regulate-able gene therapy platform. The first platform allows it to develop vehicles...

Avisol Capital Partners on Seeking Alpha | January 18, 2021

MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia

Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ETLONDON and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will host a webcast and conference call to provide an update on the Company’s AAV-hAQP1 clinical program for the treatment of radiation-induced xerostomia. The webcast will include discussion of the first cohort of patients (n=3) treated in the Company’s Phase 1 AQUAx clinical trial. Of the three patients treated in Cohort 1, one patient has reached the 12-month assessment and two have passed the six-month assessment. In these patients, the investigational gene therapy AAV-hAQP1 has been well tolerated with no dose limiting toxic...

Yahoo | December 16, 2020

MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

LONDON and NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Evercore ISI 3rd Annual HealthCONx Conference at 10:05 a.m. ET on December 3, 2020. A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. A replay of the webcast will be available for approximately 90 days following the presentation.About MeiraGTx MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core ca...

Yahoo | November 30, 2020

MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment

Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal sensitivity at 12 monthsLONDON and NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced 12-month data from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP). Statistically significant vision improvement in the dose escalation phase of the trial was sustained one year after treatment. These data were presented today as a late-breaker oral presentation at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. MeiraGTx and Janssen Pharmaceuticals, Inc. (Janssen)...

Yahoo | November 13, 2020

Read More 'MGTX' Stories Here

MGTX Price Returns

1-mo -9.60%
3-mo 8.44%
6-mo 13.78%
1-year -15.06%
3-year N/A
5-year N/A
YTD -2.38%
2020 -24.38%
2019 107.68%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6918 seconds.